A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops in Slowing the Progression of Myopia in Children
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Atropine (Primary)
- Indications Myopia
- Focus Registrational; Therapeutic Use
- Acronyms Mini-CHAMP
- Sponsors Zhaoke Guangzhou Ophthalmology Pharmaceutical
- 29 Jan 2025 Primary endpoint has been met. (Cycloplegic Autorefraction(low)), according to Vyluma media release.
- 29 Jan 2025 According to Vyluma media release, the National Medical Products Administration (NMPA) of China has accepted the drug application.
- 16 Jan 2025 Planned End Date changed from 1 Aug 2024 to 1 Jun 2025.